A Global Pivotal Study in Patients with KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of Pembrolizumab and LY3537982 vs Pembrolizumab and Placebo in those with PD-L1 50% or Pembrolizumab, Pemetrexed, Platinum Chemotherapy and LY3537982 vs Pembrolizumab, Pemetrexed, Platinum Chemotherapy and Placebo regardless of PD-L1 Expression

Sponsor:

Eli Lilly

Sponsor Study ID:

J3M-MC-JZQB

CTO #:

103968

NCT Number:

NCT06119581

Phase:

III

Protocol Type:

Treatment

Age Group:

Adults

Disease Sites:

Lung

Study Objectives:

To determine the optimal dose of LY3537982 (50 or 100 mg BID) to be administered in combination with pembrolizumab. To compare the efficacy of LY3537982 in combination with pembrolizumab versus placebo with pembrolizumab. To compare the efficacy of LY3537982 in combination with pembrolizumab versus placebo with pembrolizumab. To compare the safety profile of LY3537982 in combination with pembrolizumab and placebo with pembrolizumab.

eConsent:

Not available

Study Documents:

Open Study Documents
(MUSC NetID required for document access)